1. Systematic Screening and Therapeutic Evaluation of Glyconanoparticles with Differential Cancer Affinities for Targeted Cancer Therapy
- Author
-
Chang‐Hee Whang, Jungwoo Hong, Dohyeon Kim, Hong Ryu, Wonsik Jung, Youngju Son, Hyeongseop Keum, Jinjoo Kim, Hocheol Shin, Eugene Moon, Ilkoo Noh, Hee‐Seung Lee, and Sangyong Jon
- Subjects
Male ,Glucosamine ,Glucose ,Mechanics of Materials ,Neoplasms ,Mechanical Engineering ,Galactose ,Humans ,General Materials Science ,Mannose ,Early Detection of Cancer - Abstract
Cancer-targeting ligands used for nanomedicines have been limited mostly to antibodies, peptides, aptamers, and small molecules thus far. Here, a library of glycocalyx-mimicking nanoparticles as a platform to enable screening and identification of cancer-targeting nanomedicines is reported. Specifically, a library of 31 artificial glycopolymers composed of either homogeneous or heterogeneous display of five different sugar moieties (β-glucose, β-galactose, α-mannose, β-N-acetyl glucosamine, and β-N-acetyl galactosamine) is converted to a library of glyconanoparticles (GlyNPs). GlyNPs optimal for targeting CT26, DU145, A549, and PC3 tumors are systematically screened and identified. The cypate-conjugated GlyNP displaying α-mannose and β-N-acetyl glucosamine show selective targeting and potent photothermal therapeutic efficacy against A549 human lung tumors. The docetaxel-contained GlyNP displaying β-glucose, β-galactose, and α-mannose demonstrate targeted chemotherapy against DU145 human prostate tumors. The results presented herein collectively demonstrate that the GlyNP library is a versatile platform enabling the identification of cancer-targeting glyconanoparticles and suggest its potential applicability for targeting various diseased cells beyond cancer.
- Published
- 2022
- Full Text
- View/download PDF